Try
Roivant Sciences Ltd. Common Shares
ROIVUnited States
30 filed reports · 442 financial concepts · 2 earnings calls · 0 media appearances
Filed reports
30 reports · Jun 2021 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 77 commentary passages.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 23 | 2,630 | Jun 2021 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 7 | 2,392 | Mar 2022 to Mar 2026 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2027 Q1 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 1 | Open |
| FY2026 Q1 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 340 | Open |
| FY2025 | 10-K | Mar 31, 2026 | May 20, 2026 | 940 | Open |
| FY2026 | 10-K | Mar 31, 2026 | May 20, 2026 | 17 | Open |
| FY2025 Q3 | 10-Q | Dec 31, 2025 | Feb 6, 2026 | 270 | Open |
| FY2026 Q3 | 10-Q | Dec 31, 2025 | Feb 6, 2026 | 9 | Open |
| FY2026 Q2 | 10-Q | Sep 30, 2025 | Nov 10, 2025 | 9 | Open |
| FY2025 Q2 | 10-Q | Sep 30, 2025 | Nov 10, 2025 | 209 | Open |
| FY2025 Q1 | 10-Q | Jun 30, 2025 | Aug 11, 2025 | 146 | Open |
| FY2026 Q1 | 10-Q | Jun 30, 2025 | Aug 11, 2025 | 1 | Open |
| FY2025 | 10-K | Mar 31, 2025 | May 29, 2025 | 1 | Open |
| FY2024 | 10-K | Mar 31, 2025 | May 29, 2025 | 426 | Open |
Financial data
442 concepts · 5,022 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial417 concepts · 4,631 facts · Jun 2020 to Jul 2026
- Cash cash equivalents restricted cash and restricted cash equivalents31 · Jun 2020 to Jun 2026
- Change in fair value of debt and liability instruments31 · Jun 2020 to Jun 2026
- Comprehensive income net of tax31 · Jun 2020 to Jun 2026
- Comprehensive income net of tax attributable to noncontrolling interest31 · Jun 2020 to Jun 2026
- Comprehensive income net of tax including portion attributable to noncontrolling interest31 · Jun 2020 to Jun 2026
- Cost of revenues31 · Jun 2020 to Jun 2026
- Gain loss on investments31 · Jun 2020 to Jun 2026
- Income tax expense benefit31 · Jun 2020 to Jun 2026
- Increase decrease in accounts payable trade31 · Jun 2020 to Jun 2026
- Increase decrease in accrued liabilities31 · Jun 2020 to Jun 2026
- Net cash provided by used in financing activities31 · Jun 2020 to Jun 2026
- Net cash provided by used in investing activities31 · Jun 2020 to Jun 2026
- Net cash provided by used in operating activities31 · Jun 2020 to Jun 2026
- Net income loss31 · Jun 2020 to Jun 2026
- Net income loss attributable to noncontrolling interest31 · Jun 2020 to Jun 2026
- Operating expenses (US GAAP)31 · Jun 2020 to Jun 2026
- Operating income loss31 · Jun 2020 to Jun 2026
- Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent31 · Jun 2020 to Jun 2026
- Other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax31 · Jun 2020 to Jun 2026
- Other comprehensive income loss net of tax31 · Jun 2020 to Jun 2026
- Other noncash income expense31 · Jun 2020 to Jun 2026
- Other nonoperating income expense31 · Jun 2020 to Jun 2026
- Payments to acquire property plant and equipment31 · Jun 2020 to Jun 2026
- Profit loss31 · Jun 2020 to Jun 2026
Segment16 concepts · 210 facts · Mar 2024 to Jun 2026
- Research and development expense91 · Mar 2024 to Jun 2026
- Change in fair value of liability instruments11 · Mar 2024 to Jun 2026
- Cost of revenues11 · Mar 2024 to Jun 2026
- Gain loss on investments11 · Mar 2024 to Jun 2026
- Income tax expense benefit11 · Mar 2024 to Jun 2026
- Investment income interest11 · Mar 2024 to Jun 2026
- Other nonoperating income expense11 · Mar 2024 to Jun 2026
- Profit loss11 · Mar 2024 to Jun 2026
- Revenue11 · Mar 2024 to Jun 2026
- Gain on sale of Telavant net assets9 · Mar 2024 to Mar 2026
- Income loss from discontinued operations net of tax7 · Mar 2024 to Mar 2026
- Litigation settlement gain5 · Mar 2024 to Jun 2026
- Acquired in-process research and development3 · Mar 2024 to Mar 2026
- Deconsolidation gain or loss amount3 · Mar 2024 to Mar 2026
- Other general and administrative expense2 · Jun 2025 to Jun 2026
- Other research and development expense2 · Jun 2025 to Jun 2026
Product3 concepts · 96 facts · Mar 2022 to Mar 2026
- Research and development expense40 · Mar 2023 to Jun 2025
- R&D Expense32 · Mar 2025 to Mar 2026
- Revenue24 · Mar 2022 to Jun 2024
Geography6 concepts · 85 facts · Mar 2021 to Mar 2026
- Current income tax expense benefit24 · Mar 2021 to Mar 2026
- Deferred income tax expense benefit24 · Mar 2021 to Mar 2026
- Income loss from continuing operations before income taxes extraordinary items noncontrolling interest20 · Mar 2022 to Mar 2026
- Income loss from continuing operations before income taxes minority interest and income loss from equity method investments8 · Mar 2021 to Mar 2022
- United States5 · Mar 2022 to Mar 2026
- Pretax Income4 · Mar 2023
Segments
391 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 210 facts
- Reportable210 · Mar 2024 to Jun 2026
Product or service18 members · 96 facts
- License Milestone And Other Revenue12 · Mar 2022 to Jun 2024
- Product12 · Mar 2022 to Jun 2024
- Anti Fc Rn Franchise Dermatology Diseases5 · Mar 2023 to Jun 2025
- Anti Fc Rn Franchise Endocrine Diseases5 · Mar 2023 to Jun 2025
- Anti Fc Rn Franchise Neurological Diseases5 · Mar 2023 to Jun 2025
- Anti Fc Rn Franchise Other Clinical And Nonclinical5 · Mar 2023 to Jun 2025
- Anti Fc Rn Franchise Rheumatology Diseases5 · Mar 2023 to Jun 2025
- Brepocitinib5 · Mar 2023 to Jun 2025
- Mosliciguat5 · Mar 2023 to Jun 2025
- Other Development And Discovery Programs5 · Mar 2023 to Jun 2025
- Anti fc rn franchise dermatology diseases4 · Mar 2025 to Mar 2026
- Anti fc rn franchise endocrine diseases4 · Mar 2025 to Mar 2026
- Anti fc rn franchise neurological diseases4 · Mar 2025 to Mar 2026
- Anti fc rn franchise other clinical and nonclinical4 · Mar 2025 to Mar 2026
- Anti fc rn franchise rheumatology diseases4 · Mar 2025 to Mar 2026
- Brepocitinib4 · Mar 2025 to Mar 2026
- Mosliciguat4 · Mar 2025 to Mar 2026
- Other development and discovery programs4 · Mar 2025 to Mar 2026
Statement geographical8 members · 85 facts
- US24 · Mar 2021 to Mar 2026
- BM19 · Mar 2021 to Mar 2026
- CH19 · Mar 2021 to Mar 2026
- Other19 · Mar 2021 to Mar 2026
- Bm1 · Mar 2023
- Ch1 · Mar 2023
- Us1 · Mar 2023
- Other1 · Mar 2023
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary110 claims from 9 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary77 claims from 4 reports · Dec 2024 to Jun 2026
- Risk-factor changes34 claims from 1 reports · Mar 2026
- Risk factors195 risks from 2 annual reports · 2024 to 2025
Earnings calls
2 calls · May 2026 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2027 Q1Aug 6, 2026
- FY2026 Q4May 20, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.